Skip to main content
SpringerLink
Log in

Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies

  • Original Articles
  • CSF, Monoclonal Antibodies, ADCC, Mononuclear Cells, Granulocytes
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Unconjugated monoclonal antibodies (mAb) kill tumor cells in vivo by activating immune functions. One of these is ADCC (antibody-dependent cellular cytotoxicity). The efficacy of mAbs might be augmented if the cytotoxic capacity of the effector cells could be increased. In this study the augmenting effect of granulocyte-colony-stimulating factor (G-CSF), granulocyte/macrophage(GM)-CSF and macrophage(M)-CSF was analyzed. Effector cells [peripheral blood mononuclear cells (PBMC) or granulocytes] were activated for 4–6 h by the respective CSF and assayed in an 18-h Cr51-release assay. Human colorectal, lymphoma, glioma and melanoma cell lines were target cells. Mouse mAbs of different isotypes, as well as chimeric and humanized mAbs, were used. mAbs having the human Fc part of the IgG molecule were the most effective. The killing capacity of PBMC as well as of granulocytes was statistically significantly enhanced when mAbs were added. M-CSF and GM-CSF were the best CSF for augmenting the lytic capacity of PBMC in ADCC. G-CSF had no significant effect on PBMC. Spontaneous cytolysis of PBMC was significantly augmented only by M-CSF. Granulocytes were, in general, significantly less effective than PBMC but may be equally effective killer cells together with mouse or human mAbs of the IgG1 isotype, particularly against melanoma cells. Granulocytes may also be significantly stimulated to increased lytic capacity when activated with G-CSF or GM-CSF. On the basis of the present evaluation, clinical trials in tumor patients are warranted, combining mAbs with GM-CSF or M-CSF. Preference might be given to GM-CSF as this cytokine activates both PBMC and granulocytes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adams D, Hall T, Steplewski Z, Koprowski H (1984) Tumors undergoing rejection induced by monoclonal antibodies of the IgG2A isotype containing increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis. Proc Natl Acad Sci USA 81: 3506

    PubMed  Google Scholar 

  2. Amaout MA, Wang EA, Clark SC, Sieff CA (1986) Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. J Clin Invest 78: 597

    PubMed  Google Scholar 

  3. Arancia G, Malorni W, Donelli G (1990) Cellular mechanisms of lymphocyte-mediated lysis of tumor cells. Ann Ist Super Sanita 26: 369

    PubMed  Google Scholar 

  4. Bajorin DF, Chapman PB, Wong GY, Cody BV, Cordon-Cardo C, Dantes L, Templeton MA, Scheinberg D, Oettgen HF, Houghton AN (1992) Treatment with high dose mouse monoclonal (anti-CD3) antibody R24 in patients with metastatic melanoma. Melanoma Res 2: 355

    PubMed  Google Scholar 

  5. Baldwin GC, Chung GY, Kaslander C, Esmail T, Reisfeld RA, Golde DW (1993) Colony-stimulating factor enhancement of myeloid effector cell cytotoxicity towards neuroectodermal tumour cells. Br J Haematol 83: 545

    PubMed  Google Scholar 

  6. Barker E, Reisfeld RA (1993) A mechanism for neutrophil-mediated lysis of human neuroblastoma cells. Cancer Res 53: 362

    PubMed  Google Scholar 

  7. Blaszczyk-Thurin M, Thurin J, Hindsgaul O, Karlsson K-A, Steplewski Z, Koprowski H (1987) Y and blood group B type 2 glycolipid antigens accumulate in a human gastric carcinoma cell line as detected by monoclonal antibody: isolation and characterization by mass spectrometry and NMR spectroscopy. J Biol Chem 262: 372

    PubMed  Google Scholar 

  8. Boente P, Sampaio C, Brandao MA, Moreira ED, Badaro R, Jones TC (1993) Local peri-lesional therapy with rhGM-CSF for Kaposi's sarcoma. Lancet 341: 1154

    Google Scholar 

  9. Borrebaeck CAK (1986) In vitro immunization for production of murine and human monoclonal antibodies: present status. Trends Biotechnol 4: 147

    Google Scholar 

  10. Böyum A (1968) A one stage procedure for isolation of granulocytes and lymphocytes from human blood. Scand J Clin Lab Invest 21: 77

    PubMed  Google Scholar 

  11. Böyum A (1983) Isolation of human blood monocytes with Nycodenz, a new non-ionic iodinated gradient medium. Scand J Immunol 17: 429

    PubMed  Google Scholar 

  12. Brown SL, Miller RA, Horning SJ, Czerwinski D, Hart SM, McElderry R, Basham T, Warnke RA, Merigan TC, Levy R (1989) Treatment of B cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 73: 651

    PubMed  Google Scholar 

  13. Cannistra SA, Vellenga E, Groshek P, Rambaldi A, Griffin JD (1988) Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood 71: 672

    PubMed  Google Scholar 

  14. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J (1993) GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 360: 258

    Google Scholar 

  15. Charak BS, Agah R, Mazumder A (1993) Granulocyte-macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow macrophages: application in bone marrow transplantation. Blood 81: 3474

    PubMed  Google Scholar 

  16. Denkers EY, Badger CC, Ledbetter JA, Bernstein ID (1985) Influence of antibody isotype on passive serotherapy of lymphoma. J Immunol 135: 2183

    PubMed  Google Scholar 

  17. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539

    PubMed  Google Scholar 

  18. Dyer MJS, Hale G, Hayhoe FGJ, Waldman H (1989) Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73: 1431

    PubMed  Google Scholar 

  19. Elliott MJ, Vadas MA, Cleland LG, Gamble JR, Lopez AF (1990) IL-3 and granulocyte-macrophage colony-stimulating factor stimulate two distinct phases of adhesion in human monocytes. J Immunol 145: 167

    PubMed  Google Scholar 

  20. Fabian J, Baldwin GC, Golde DW (1987) Biosynthetic granulocyte-macrophage colony-stimulating factor enhances neutrophil cytotoxicity toward human leukemia cells. Leukemia 1: 613

    PubMed  Google Scholar 

  21. Ferrante A, Thong YH (1980) Optimal conditions for simultaneous purification of mononuclear and polymorphonuclear leucocytes from human flood by the Hypaque-Ficoll method. J Immunol Methods 36: 109

    PubMed  Google Scholar 

  22. Gerrard TL, Cohen DJ, Kaplan AM (1981) Human neutrophilmediated cytotoxicity to tumor cells. J Natl Cancer Inst 66: 483

    PubMed  Google Scholar 

  23. Graziano RF, Looney RJ, Shen L, Fanger MW (1989) Fc..R mediated killing by eosinophils. J Immunol 142: 230

    PubMed  Google Scholar 

  24. Griffin JD, Cannistra SA, Sullivan R, Demetri GD, Ernst TJ, Kanakura Y (1990) The biology of GM-CSF: regulation of production and interaction with its receptor. Int J Cell Cloning 8: 35

    PubMed  Google Scholar 

  25. Hafeman DG, Lucas ZJ (1979) Polymorphnuclear leukocyte-mediated antibody-dependent cellular cytotoxicity against tumor cells: dependence on oxygen and the respiratory burst. J Immunol 123: 55

    PubMed  Google Scholar 

  26. Hale G, Dyer MJS, Clark MR, Phillips JM, Marcus RE, Riechmann L, Winter G, Waldman H (1988) Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-IH. Lancet 2: 1395

    Google Scholar 

  27. Hamilton TA, Adams DO (1987) Molecular mechanisms of signal transduction in macrophages. Immunol Today 8: 151

    Google Scholar 

  28. Herberman RB, Holden HT (1978) Natural cell-mediated immunity. Adv Cancer Res 27: 305

    PubMed  Google Scholar 

  29. Herlyn D, Herlyn M, Steplewski Z, Koprowski H (1979) Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma. Eur J Immunol 9: 657

    PubMed  Google Scholar 

  30. Herlyn D, Herlyn M, Steplewski Z, Koprowski H (1985) Monoclonal anti-human tumor antibodies of six isotypes in cytotoxic reactions with human and murine effector cells. Cell Immunol 92: 105

    PubMed  Google Scholar 

  31. Hibbs JB, Lambert L, Remington J (1972) Possible role of the macro-phage-mediated nonspecific cytotoxicity in tumor resistance. Nature 235: 48

    Google Scholar 

  32. Hiopoulos D, Ernst C, Steplewski Z, Jambrosic JA, Rodeck U, Herlyn M, Clark WH Jr, Koprowski H, Herlyn D (1989) Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. J Natl Cancer Inst 81: 440

    PubMed  Google Scholar 

  33. Johnson WJ, Steplewski Z, Matthews TJ, Hamilton TA, Koprowski H, Adams DO (1986) Cytolytic interaction between murine macrophages, tumor cells and monoclonal antibodies: characterization of lytic condition and requirements for effector activation. J Immunol 136: 4704

    PubMed  Google Scholar 

  34. Kaminski MS, Kitamora K, Maloney DG, Campbell MJ, Levy R (1986) Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J Immunol 136: 1123

    PubMed  Google Scholar 

  35. Kushner BH, Cheung N-KV (1992) Absolute requirement of CD11/CD18 adhesion molecules, FcRII, and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity. Blooc 79: 1484

    Google Scholar 

  36. Liesveld JL, Abboud CN, Looney RJ, Ryan DH, Brennan JK (1988) Expression of IgG Fc receptors in myeloid leukemic cell lines. Effect of colony-stimulating factors and cytokines. J Immunol 140: 1527

    PubMed  Google Scholar 

  37. Lindemalm C, Mellstedt H, Biberfeld P, Björkholm M, Christensson B, Holm G, Johansson B, Sundblad R (1983) Blood and lymph node T lymphocyte subsets in non-Hodgkin lymphomas. Scand J Haematol 30: 68

    PubMed  Google Scholar 

  38. Lowder JN, Meeker TC, Campbell M, Carcia CF, Gralow J, Miller RA, Warnke R, Levy R (1987) Studies on B lymphoid tumors treated with monoclonal anti-idotype-antibodies: correlation with clinical responses. Blood 69: 199

    PubMed  Google Scholar 

  39. Lundgren G, Zubrowski CHF, Möller G (1968) Differential effects of human granulocytes on lymphocytes on human fibroblasts. Clin Exp Immunol 3: 817

    PubMed  Google Scholar 

  40. Majima T, Ohashi Y, Nagatomi R, Iizuka A, Konno T (1993) Defective mononuclear cell antibody dependent cellular cytotoxicity (ADCC) in patients with leukocyte adhesion deficiency emphasizing on different CD11/CD18 requirement of Fc..RI versus Fc..RII in ADCC. Cell Immunol 148: 385

    PubMed  Google Scholar 

  41. Masucci G, Lindemalm C, Frödin J-E, Hagström B, Mellstedt H (1988) Effect of human blood mononuclear cell populations in antibody dependent cellular cytotoxicity (ADCC) using two murine (CO17-1A and Br55-2) and one chimeric (17-1A) monoclonal antibodies against a human colorectal carcinoma cell line (SW948). Hybridoma 7: 429

    PubMed  Google Scholar 

  42. Mellstedt H (1994) Unconjugated monoclonal antibodies in cancer treatment — the story so far. Oncol Today 9: 9

    Google Scholar 

  43. Munn DH, Cheung N-KV (1989) Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. J Exp Med 170: 511

    PubMed  Google Scholar 

  44. Munn DN, McBride M, Cheung N-KV (1991) Role of low-affinity Fc receptors in antibody-dependent tumor cell phagocytosis by human monocyte-derived macrophages. Cancer Res 51: 1117

    PubMed  Google Scholar 

  45. Ortaldo JR, Woodhouse C, Morgan AC, Herberman RB, Cheresh DA, Reisfeld R (1987) Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies. J Immunol 138: 3566

    PubMed  Google Scholar 

  46. Ragnhammar P, Fagerberg J, Frödin J-E, Hjelm A-L, Lindemalm C, Magnusson I, Masucci G, Mellstedt H (1993) Effect of the monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma—long lasting, complete remissions can be induced. Int J Cancer 53: 751

    PubMed  Google Scholar 

  47. Repp R, Valerius Th, Sendler A, Graniatzki M, Iro H, Kalden JR, Platzer E (1991) Neutrophils express the high affinity receptor for IgG (Fc..RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor. Blood 78: 885

    PubMed  Google Scholar 

  48. Robin G, Markovich S, Athamna A, Keisari Y (1991) Human recombinant granulocyte-macrophage colony-stimulating factor augments viability and cytotoxic activities of human monocyte-derived macrophages in long-term cultures. Lymphokine Cytokine Res 10: 257

    PubMed  Google Scholar 

  49. Rodeck U, Herlyn M, Herlyn D, Molthoff C, Atkinson B, Varello M, Steplewski Z, Koprowski H (1987) Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effects. Cancer Res 47: 3692

    PubMed  Google Scholar 

  50. Sanda MG, Yang JC, Topalian SL, Groves ES, Childs A, Belfort Jr R, de Smet MD, Schwartzentruber DJ, White DE, Lotze MT, Rosenberg SA (1992) Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase 1 study. J Clin Oncol 10: 1643

    PubMed  Google Scholar 

  51. Shaw DR, Khazaeli MB, Sun LK, Grhayeb J, Daddona PE, McKinney S, LoBulgio AF (1987) Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen. J Immunol 138: 4534

    PubMed  Google Scholar 

  52. Shetye J, Frödin J-E, Christensson B, Grant C, Jacobsson B, Sundelius S, Sylvén M, Biberfeld P, Mellstedt H (1988) Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (mAb 17-1A). Cancer Immunol Immunother 27: 154

    PubMed  Google Scholar 

  53. Steplewski Z, Herlyn D, Lubeck M, Kimoto Y, Herlyn M, Koprowski H (1986) Mechanism of tumor growth inhibition. Hybridoma 5: 59

    Google Scholar 

  54. Sullivan GW, Carper HT, Mandell GL (1993) The effect of three human recombinant hematopoietic growth factors (granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor, and interleukin-3) on phagocyte oxidative activity. Blood 81: 1863

    PubMed  Google Scholar 

  55. Sun LK, Curtis P, Rakowicz-Szulezynska E, Ghrayeb J, Morrison SL, Chang N, Koprowski H (1986) Chimeric antibodies with 17-1A-derived variable and human constant regions. Hybridoma 5: 17

    Google Scholar 

  56. Unkeless JC (1989) Function and heterogeneity of human Fc receptors for immunoglobulin G. J Clin Invest 83: 355

    PubMed  Google Scholar 

  57. Vairo G, Hamilton JA (1991) Signalling through CSF receptors. Immunol Today 12: 362

    PubMed  Google Scholar 

  58. Wing EJ, Magee DM, Whiteside TL, Kaplan SS, Shadduck RK (1989) Re-combinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor α and interferon in cancer patients. Blood 73: 643

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology (Radiumhemmet) and Immunological Research Laboratory, Karolinska Hospital, S-171 76, Stockholm, Sweden

    P. Ragnhammar, J. -E. Frödin & H. Mellstedt

  2. Schering-Plough Research Institute, Kenilworth, N.J., USA

    P. P. Trotta

Authors
  1. P. Ragnhammar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. -E. Frödin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. P. Trotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Mellstedt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ragnhammar, P., Frödin, J.E., Trotta, P.P. et al. Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies. Cancer Immunol Immunother 39, 254–262 (1994). https://doi.org/10.1007/BF01525989

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01525989

Key words

Search

Navigation